P106

Hospital Universitario **Virgen del Rocío**

Servicio Andaluz de Salud
CONSEJERÍA DE SALUD

Effectiveness and safety of Doravirine from a real-world HIV cohort: DORWINS study

Espinosa N[1], Mejías -Trueba M[1,2], Gutiérrez-Valencia A[1], Llaves-Flores S[1], Herrero M[1], Sotomayor C[1], Roca C[1], Rodríguez MJ[1], López Cortés LF[1].
[1]Clinical Unit of Infectious Diseases and Microbiology, Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla. Seville, Spain
[2]UGC de Farmacia. Hospital Universitario Virgen del Rocío. Seville. Spain

BACKGROUND

Doravirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) which has demonstrated long-term safety and efficacy as an antiretroviral (ART) switch strategy in clinical trials, with a higher genetic barrier and fewer drug interactions than alternatives from the same family.

OBJECTIVES

The objective is to evaluate the **effectiveness**, **safety**, and **tolerability** of doravirine **at week 48** in a real-world HIV cohort

METHODS

- Design --> observational and ambispective single-centre cohort study.
- Participants --> HIV-infected patients who switched to a doravirine-based regimen.
- Period: October 2020 to March 2022.
- Variables evaluated --> **Effectiveness**: defined as the proportion of patients with a viral load (VL) ≤ 50 and ≤200 copies/ml at week 48.

Routinely clinical and laboratory data were collected every 1-6 months based on clinical criteria.

RESULTS

189 patients

Table I: Baseline demographic characteristics

Males, no. (%)	160 (84.7)
Age, (range), years	51.8 (43.5-57.5)
CD4/µl, M (range)	684 (527 - 883)
VL ≤ 50 cp/mL, no. (%)	171 (90.5)
Duration of HIV infection (range), years	14 (8-27)
Median of previous ART-regimens	5 (4-9)
Most prescribed combination, %	
DOR+3TC+ABV	58.2%
DOR+FTC+TDF	19.6%
DOR+DTG	13.2%
Resistance mutations (n=85), %	
184V/I	9.5%
103N/R/Q	8.5%
138K/A/G	3.2%
190A	1.6%



Figure I: 48 w efectiveness

Median follow-up was **13.4 (IQR;6.63-17.36)** months:

a. Doravirine was discontinued in **20 patients (10.6%)**:
   AE (5.2%), patient decision (2.1%), physician decision (2.1%), virological failure (0.5%) and withdrawal (0.5%).
b. All **AEs** were mild and self-limited.
   No changes in immunological parameters, weight, lipid, liver, and renal profile were observed.
c. EFFECTIVENESS in an **ITT** analysis at week 48 was **89.4%.**
d. In the analysis **PP**: **95.3%** patients had **VL ≤ 50** and **98.8%** patients had **≤200 copies/ml** at week 48.

CONCLUSIONS

In our experience, doravirine is an **effective** and **safe** switch strategy in a real-world setting even in treatment-experienced HIV patients.

Supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme LLC